Previous close | 4.8000 |
Open | N/A |
Bid | 0.5500 |
Ask | 5.0000 |
Strike | 30.00 |
Expiry date | 2024-12-20 |
Day's range | 4.8000 - 4.8000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June: Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, June 5Time: 8:30 a.m. ET Goldman Sachs Annual Global Healthcare ConferenceFormat: Fireside C
Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focu
Coliseum Capital increased its stake in boat maker MasterCraft. Insight Venture Partners sold shares of cybersecurity firm SentinelOne.